Enhancement of Pancreatic Carcinogenesis by Dehydroepiandrosterone

  • Anthony R. Tagliaferro
  • B. D. Roebuck
  • Anne M. Ronan
  • Loren D. Meeker
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 322)


Caloric intake and body weight have been established as positive risk factors in the development of several human cancers.1 Conversely, caloric restriction has been found to significantly inhibit spontaneous2,3 as well as chemically induced mammary carcinogenesis4,5 and pancreatic pre-neoplastic foci6 in laboratory rodents.


Rest Energy Expenditure Negative Energy Balance Granulosa Cell Tumor Pancreatic Carcinogenesis Focus Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cancer In: U.S. Dept of Health and Human Services, Public Health Service, DHHS (PHS) Publication No. 88–50210, The Surgeon General’s Report on Nutrition and Health. U.S. Government Printing Office, Washington, DC (1988).Google Scholar
  2. 2.
    A. Tannenbaum, Initiation and growth of tumors. I. effects of underfeeding, Amer. J Cancer. 38: 335 (1940).Google Scholar
  3. 3.
    M.J. Tucker, The effects of long-term food restriction on tumors in rodents, Int J Cancer. 23: 803 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    D. Kritchevsky and D.M. Klurfeld, Calorific effects on experimental mammary tumorigenesis, Am J Clin Nutr. 45: 236 (1987).PubMedGoogle Scholar
  5. 5.
    M.W. Pariza, Fat, calories and mammary carcinogenesis: net energy effects, Am J Clin Nutr. 45: 261 (1987).PubMedGoogle Scholar
  6. 6.
    B.D. Roebuck, J.D. Yager, D.S. Longnecker, and S.A. Wilpone, Promotion by unsaturated fat on azaserine-induced pancreatic carcinogenesis in the rat, Cancer Res. 41: 3961 (1981).PubMedGoogle Scholar
  7. 7.
    G.B. Gordon, L.M. Shantz, and P. Talalay, Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Advances in Enzyme Regulation. 26: 355 (1987).PubMedCrossRefGoogle Scholar
  8. 8.
    N. Orentreich, J.L. Brind, L. Rizer, and J.H. Vogelman, Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood, J Clin Endocrinal Metab 59: 551 (1984).CrossRefGoogle Scholar
  9. 9.
    J. Sonka, Dehydroepiandrosterone metabolic effects. Acta Universitatis Carolinae Medica. 71: 1 (1976).Google Scholar
  10. 10.
    E. Barrett-Connor, K. Khaw, and S.S.C. Yen, A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease, N Engl J Med. 315: 1519 (1986).PubMedCrossRefGoogle Scholar
  11. 11.
    M.P. Cleary, Antiobesity effect of dehydroepiandrosterone in the Zucker rat, in: “Hormones and Thermogenesis and Obesity,” H. Lardy and F. Strathan, eds., Elsevier, New York (1989).Google Scholar
  12. 12.
    A.G. Schwartz, Inhibition of spontaneous breast cancer formation in female C3H (A“Y/a) mice by long-term treatment with dehydroepiandrosterone, Cancer Res. 39: 1129 (1979).PubMedGoogle Scholar
  13. 13.
    A.G. Schwartz and R.H. Tanner, Inhibition of 7,12-dimethylbenz(a)anthracene-and urethan-induced lung tumor formation in NJ mice by long-term treatment with dehydroepiandrosterone, Carcinogenesis. 2: 1335 (1981).PubMedCrossRefGoogle Scholar
  14. 14.
    J.W. Nyce, P.N. Magee, G.C. Hard, and A.G. Schwartz, Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone, Carcinogenesis. 5: 57 (1984).PubMedCrossRefGoogle Scholar
  15. 15.
    Y. Arad, J. Badimon, and L. Badimon, Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbits, Arteriosclerosis, 9: 159 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    M.P. Cleary, A. Shepherd, and B. Jenks, Effect of dehydroepiandrosterone on growth in lean and obese Zucker rats, J Nutr. 114: 1242 (1984).PubMedGoogle Scholar
  17. 17.
    A.R. Tagliaferro, J.R. Davis, S.T. Truchon, and N. Van Hamont, Effects of dehydroepiandrosterone acetate on metabolism, body weight and composition of male and female rats, J Nutr. 116: 1977 (1986).PubMedGoogle Scholar
  18. 18.
    J.E. Nestler, C.O. Bartascini, J.N. Clore, and W.G. Blackard, Dehydroepiandrosterone effects on insulin sensitivity, serum lipids levels, and body composition in normal men, in: “Hormones and Thermogenesis and Obesity,” H. Lardy and R. Stratman, eds., Elsevier, New York (1989).Google Scholar
  19. 19.
    K.S. Usiskin, S. Butterworth, J.N. Clore, Y. Arad, H.N. Ginsberg, W.G. Blackard, and S.E. Nestler, Lack of effect of dehydroepiandrosterone in obese men, International J of Obesity, 14: 457 (1990).Google Scholar
  20. 20.
    C.W. Boone, G.J. Kelloff, and W.E. Malone, Identification of candidate chemopreventative agents and their evaluation in animal models and human clinical trials: a review, Cancer Res. 50: 2 (1990).PubMedGoogle Scholar
  21. 21.
    S. Welle, R. Jozefowicz, and M. Statt, Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans, J. Clin. Endocrinol Metab. 71: 1259 (1990).PubMedCrossRefGoogle Scholar
  22. 22.
    D.L. Coleman, Therapeutic effects of dehydroepiandrosterone and its metabolites in diabetes-obesity mutants, in: “Hormones and Thermogenesis and Obesity,” H. Lardy and R. Stratman, eds., Elsevier, New York (1989).Google Scholar
  23. 23.
    P.A. Marks and J. Banks, Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids, Proc. Natl. Acad. Sci. USA 46: 447 (1960).PubMedCrossRefGoogle Scholar
  24. 24.
    A.C. Finan and M.D. Cleary, Lack of an effect of short-term dehydropeiandrosterone treatment on the pentose pathway, Nutrition Res. 8: 755 (1988).CrossRefGoogle Scholar
  25. 25.
    J.P. Casazza, W.T. Schaeffer, and R.L. Veech, The effect of dehydroepiandrosterone on liver metabolites, J Nutr. 116: 304 (1986).PubMedGoogle Scholar
  26. 26.
    H.M. Tepperman, S.A. De La Garza, and J. Tepperman, Effects of dehydroepiandrosterone and diet protein on liver enzymes and lipogenesis, Am J Physiol. 214: 1126 (1968).PubMedGoogle Scholar
  27. 27.
    D.A. Diersen-Schadue and M.P. Cleary, No effect of long-term DHEA treatment on either hepatocyte and adipocyte pentose pathway activity or adipocyte glycerol release, Horm Metabol Res. 21: 356 (1988).CrossRefGoogle Scholar
  28. 28.
    M.P. Cleary, The antiobesity effect of dehydroepiandrosterone in rats, Proc Soc Exp Biol Med. 196: 8 (1991).PubMedGoogle Scholar
  29. 29.
    W.G. Beamer, K.L. Shultz, and B.J. Tennent, Induction of ovarian granulosa cell tumors in SWXJ-9 mice with dehydroepiandrosterone, Cancer Res. 48: 2788 (1988).PubMedGoogle Scholar
  30. 30.
    M. Thornton, M.A. Moore, and N. Ito, Modifying influence of dehydroepiandrosterone or butylated hydroxytoluene treatment on initiation and development states of azaserineinduced acinar pancreatic preneoplastic lesions in the rat, Carcinogenesis. 10: 407 (1989).PubMedCrossRefGoogle Scholar
  31. 31.
    Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies, J Nutr. 107: 1340 (1977).Google Scholar
  32. 32.
    B.D. Roebuck, D.S. Longnecker, K.J. Baumgartner, and C.D. Thron, Carcinogen-induced lesions in the rat pancreas: effects on varying levels of essential fatty acid, Cancer Res. 45: 5252 (1985)PubMedGoogle Scholar
  33. 33.
    H.J. Thompson, A.M. Ronan, K.A. Ritacco, A.R. Tagliaferro, and L.D. Meeker, Effect of exercise on the induction of mammary carcinogenesis, Cancer Res. 48: 2720 (1988).PubMedGoogle Scholar
  34. 34.
    B.D. Roebuck, K.J. Baumgartner, and C.D. Thron, Characterization of two populations of pancreatic atypical acinar cell foci induced by azaserine in the rat, Lab Invest. 50: 141 (1984).PubMedGoogle Scholar
  35. 35.
    T.D. Pugh, J.H. King, H. Koen, D. Nuchka, J. Choyer, G. Wahba, Y. He, and S. Goldfarb, Reliable stereological method for estimating the number of microscopic hepatocellular foci from their transections, Cancer Res. 43: 1261 (1983).PubMedGoogle Scholar
  36. 36.
    G.W. Snedecor and W.G. Cochran, “Statistical Methods,” Ed 6. University of Iowa Press, Ames, IA. (1967).Google Scholar
  37. 37.
    B. Leighton, A.R. Tagliaferro, and E.A. Newsholme, The effect of dehydroepiandrosterone acetate on liver peroxisomal enzyme activities of male and female rats, J Nutr. 117: 1287 (1987).PubMedGoogle Scholar
  38. 38.
    P.F. Mohan and M.P. Cleary, Comparison of dehydroepiandrosterone and clofibric acid treatment in obese Zucker rats, J Nutr. 119: 496 (1989).PubMedGoogle Scholar
  39. 39.
    H. Lardy, S. Ching-yuan, N. Kneer, and S. Wielgus, Dehydroepiandrosterone induces enzymes that permit thermogenesis and decrease metabolic efficiency, in: “Hormones and Thermogenesis and Obesity,” H. Lardy and R. Stratman, eds., Elsevier, New York (1989).Google Scholar
  40. 40.
    C. Sumi, D.S. Longnecker, B.D. Roebuck, and T. Brinck-Johnsen, Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine, Cancer Res. 49: 2332 (1989).PubMedGoogle Scholar
  41. 41.
    L.A. Sauer, W.O. Nagel, R.T. Dauchy, L.A. Miceli, and J.E. Austin, Stimulation of tumor growth in adult rats in vivo during an acute fast, Cancer Res. 46: 3469 (1986).PubMedGoogle Scholar
  42. 42.
    L.A. Sauer and R.T. Dauchy, Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes, Cancer Res. 47: 1756 (1987).PubMedGoogle Scholar
  43. 43.
    X. Xu, G. DePergola, and P. Bjomtorp, The effects of androgens on the regulation of lipolysis in adipose precursor cells, Endocrinology. 126: 1229 (1990).PubMedCrossRefGoogle Scholar
  44. 44.
    E.H. Leiter, W.G. Beamer, D.L. Coleman, and C. Longscope, Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: relationship to antihyperglycemic effects, Metabolism. 36 (9): 863 (1987).PubMedCrossRefGoogle Scholar
  45. 45.
    A. Meisler, Glutathione metabolism and its selective modification, J Biol Chem. 263 (33): 17205 (1988).Google Scholar
  46. 46.
    H. Wu, J. Masset-Brown, D.J. Tweedie, L. Milewich, and R.A. Frenkel, Induction of microsomal NADPH-cytochrome P-450 reductose and cytochrome P-4501VA1 (p-450 LACO) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator, Can Res 49: 2337 (1989).Google Scholar
  47. 47.
    R.A. Frenkel, C.A. Slaughter, K. Orth, C.R. Moomaw, and S.H. Hicks, Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding, J. Steroid Biochem. 35 (2): 333 (1990).PubMedCrossRefGoogle Scholar
  48. 48.
    M.S. Rao and J.K. Reddy, Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis. 8 (5): 631 (1987).PubMedCrossRefGoogle Scholar
  49. 49.
    A.G. Schwartz, D.K. Fairman, M. Polansky, M.L. Lewbart, and L.L. Pashko, Inhibition of 7,12-dimethylbenz(a)anthracene-initiated and 12–0-tetradecanoylphorbol-13-acetate promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs, Carcinogenesis. 10 (10): 1809 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1992

Authors and Affiliations

  • Anthony R. Tagliaferro
    • 1
  • B. D. Roebuck
    • 2
  • Anne M. Ronan
    • 1
  • Loren D. Meeker
    • 3
  1. 1.Department of Animal and Nutritional SciencesUniversity of New HampshireDurhamUSA
  2. 2.Department of Pharmacology and ToxicologyDartmouth Medical SchoolHanoverUSA
  3. 3.Department of MathematicsUniversity of New HampshireDurhamUSA

Personalised recommendations